$BRO

Key facts: Brown & Brown (BRO) Q3 revenue $1.7B, adj EPS $1.07; Live call on TradingView

Brown & Brown (BRO) reported Q3 revenue of $1.7B, up 7.4% YoY, and adjusted EPS of $1.07. Adjusted EBITDAC margin decreased by 200 bps. Retail outperformed, while Specialty lagged. The company expects improved organic growth by 2027. The Q3 2026 earnings call is live on TradingView.

Original reporting
Published Oct 28, 2026, 7:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 7:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Key facts: Brown & Brown (BRO) Q3 revenue $1.7B, adj EPS $1.07; Live call on TradingView — source image
Decision brief

The 30-second read

$BRONeutralMed
01

Why it matters

The mixed earnings results may lead to a short‑term price adjustment as traders digest the margin decline.

02

Market read

Mid‑cap insurer with new earnings data; relevant for insurance sector and earnings‑driven traders.

03

What to watch

Potential upside from upcoming organic growth initiatives announced for 2027.

Relevance 8/10Novelty 8/10Timing: live earnings call today

Background

Brown & Brown released its Q3 2026 earnings, highlighting revenue growth and margin pressure.

Company-level read

Ticker impact

$BRONeutralHigh confidence
Context

Q3 2026 revenue $1.7B (+7.4% YoY) and adjusted EPS $1.07 were disclosed, with adjusted EBITDAC margin down 200 bps.

Expected impact

likely modest pressure as investors weigh lower margin against revenue growth

Evidence & confidence

Revenue beat suggests growth, but 200‑bp margin decline signals cost pressure, leading to a balanced market reaction.

Market effects

Insurance brokerage sector may see broader scrutiny of margin trends.

U.S. market participants may adjust exposure to mid‑cap insurers.

Limited; primarily U.S. investors.

Counterpoint

Margin compression could signal deeper cost issues, making the stock a short candidate despite revenue beat.

Key entities

  • Brown & Brown

    U.S. insurance brokerage firm.

Related articles

$BROHighAI 8/10

Why Brown & Brown Stock Slumped by 5% Today

Brown & Brown (BRO) stock fell 5% after Q3 earnings missed estimates. Revenue rose 7% YoY to $1.73B, below the $1.76B consensus. GAAP net income increased 6% to $240M, while adjusted EPS grew 2% to $1.07, missing the $1.09 estimate. The company cited a challenging rate environment and attributed some growth to its Accession acquisition, but organic revenue grew only 1% YoY to $1.46B.

$BROMed

Brown & Brown Inc (BRO) (Q3 2026) Earnings Call Highlights: Revenue Up 7.4%

Brown & Brown Inc (BRO) reported Q3 2026 revenue up 7.4% to $1.07B, but adjusted EBITDAC margin fell 200 bps to 34.6%. Specialty Distribution organic revenue declined 0.8%, missing expectations due to competition and pricing pressures. The company anticipates further declines in Q4 and faces ongoing litigation impacts. Integration costs for Accession have increased to $250-300M.

$BROMed

What Brown & Brown (BRO) Said on Its Q3 Earnings Call

Brown & Brown (BRO) reported Q3 earnings, noting market shifts in California and Texas, and pricing pressures in commercial earthquake business. The company expects 2027 growth of 2%-4% for retail and 1%-3% for specialty distribution. Accession acquisition raised synergy targets to $50M for 2026 and $175M by 2028. AI initiatives are expanding across the company, with tools like Claude and COMPASS being deployed. The board increased the dividend by 9%.

$BROHighAI 8/10

Brown & Brown (BRO) Q3 2026 Earnings Call Transcript

Brown & Brown (BRO) reported Q3 2026 revenues of $1.7B, up 7.4% YoY. Organic revenue grew 1.2%, while adjusted EBITDAC margin fell 200 bps to 34.6%. Adjusted EPS rose 2% to $1.07. The company raised its dividend by 9%, marking 33 consecutive years of increases. Retail segment outperformed expectations, while specialty distribution faced headwinds. The company repurchased $750M in shares YTD, including $250M in Q3.

$BROMed

Truist cuts Brown & Brown stock price target to $85 on lower estimates

Truist Securities reduced its price target for Brown & Brown (NYSE:BRO) to $85 from $90, citing lower 2026 and 2027 EPS estimates. The firm maintained a Buy rating, basing the target on a 14x multiple of its 2027 EBITDA estimate. BRO's Q3 earnings missed expectations, with revenue at $1.72B and EPS at $1.07, though both showed year-over-year growth. The company's organic growth slowed, and its adjusted EBITDAC margin declined by 200 basis points.